Aminopterin Clinical Trials

All Categories Medications / Interventions » Aa » Aminopterin

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Erlotinib; Drug: Pralatrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib; Drug: Pralatrexate; Drug: Romidepsin; Drug: Gemcitabine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients

Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Pralatrexate Injection; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified March 2012
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Conditions: Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma
Interventions: Drug: prednisone; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Drug: pralatrexate; Other: laboratory biomarker analysis; Genetic: comparative genomic hybridization; Genetic: gene expression analysis; Genetic: nucleic acid sequencing; Genetic: mutation analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: RNA analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pralatrexate; Drug: fluorouracil; Other: laboratory biomarker analysis; Genetic: DNA analysis; Other: high performance liquid chromatography; Genetic: polymerase chain reaction; Genetic: nucleic acid sequencing; Other: pharmacological study; Other: pharmacogenomic studies; Genetic: polymorphism analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified August 2011
Phase II of Carbo/Pralatrexate in Rec. Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: pralatrexate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Comprehensive Cancer Network
Recruiting - verified April 2012
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Recurrent Esophageal Cancer; Recurrent Gastric Cancer; Squamous Cell Carcinoma of the Esophagus; Stage III Esophageal Cancer; Stage III Gastric Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer
Interventions: Drug: pralatrexate; Drug: oxaliplatin; Other: pharmacogenomic studies; Genetic: RNA analysis; Genetic: polymorphism analysis; Genetic: polymerase chain reaction; Genetic: microarray analysis; Procedure: esophagogastroduodenoscopy; Procedure: biopsy; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified January 2012
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Conditions: Cutaneous T-cell Lymphoma; Mycosis Fungoides; Sezary Syndrome; Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions: Drug: Pralatrexate Injection; Drug: Bexarotene Capsules; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified January 2012
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

Conditions: Adenocarcinoma of the Esophagus; Adenocarcinomas of the Gastroesophageal Junction; Recurrent Esophageal Cancer; Squamous Cell Carcinoma of the Esophagus; Stage IV Esophageal Cancer
Interventions: Drug: pralatrexate; Drug: docetaxel; Radiation: fludeoxyglucose F 18; Procedure: positron emission tomography
Sponsors: Ohio State University Comprehensive Cancer Center; Jeffrey Rose; National Comprehensive Cancer Network
Recruiting - verified May 2012
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Condition: Lymphoma, B-Cell
Interventions: Drug: Pralatrexate Injection; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified October 2011